- Home
- HYPR vs ANL Comparison
HYPR vs ANL Comparison
Compare HYPR & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HYPR
- ANL
- Stock Information
- Founded
- HYPR 2014
- ANL 2004
- Country
- HYPR United States
- ANL Cayman Islands
- Employees
- HYPR N/A
- ANL N/A
- Industry
- HYPR Medical Specialities
- ANL
- Sector
- HYPR Health Care
- ANL
- Exchange
- HYPR Nasdaq
- ANL Nasdaq
- Market Cap
- HYPR 55.9M
- ANL 56.0M
- IPO Year
- HYPR N/A
- ANL 2023
- Fundamental
- Price
- HYPR $1.08
- ANL $1.44
- Analyst Decision
- HYPR Strong Buy
- ANL Hold
- Analyst Count
- HYPR 3
- ANL 1
- Target Price
- HYPR $1.06
- ANL N/A
- AVG Volume (30 Days)
- HYPR 459.6K
- ANL 6.1K
- Earning Date
- HYPR 08-07-2025
- ANL 08-08-2025
- Dividend Yield
- HYPR N/A
- ANL N/A
- EPS Growth
- HYPR N/A
- ANL N/A
- EPS
- HYPR N/A
- ANL N/A
- Revenue
- HYPR $11,732,000.00
- ANL N/A
- Revenue This Year
- HYPR $12.31
- ANL N/A
- Revenue Next Year
- HYPR $29.29
- ANL N/A
- P/E Ratio
- HYPR N/A
- ANL N/A
- Revenue Growth
- HYPR 0.34
- ANL N/A
- 52 Week Low
- HYPR $0.53
- ANL $1.10
- 52 Week High
- HYPR $1.90
- ANL $3.89
- Technical
- Relative Strength Index (RSI)
- HYPR 66.05
- ANL 42.36
- Support Level
- HYPR $0.91
- ANL $1.48
- Resistance Level
- HYPR $1.20
- ANL $1.55
- Average True Range (ATR)
- HYPR 0.09
- ANL 0.05
- MACD
- HYPR 0.03
- ANL 0.00
- Stochastic Oscillator
- HYPR 72.73
- ANL 5.00
About HYPR Hyperfine Inc.
Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales which consist of sales from subscriptions of bundled devices, maintenance, and software.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.